3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
3
Phase 1
2
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
24
Carcinoma, Renal Cell
16
Stomach Neoplasms
9
Lung Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Carcinoma, Hepatocellular
6
Kidney Neoplasms
5
Brain Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Mesothelioma
4
Adenocarcinoma Of Esophagus
4
Skin Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Anus Neoplasms
3
Various Advanced Cancer
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Mesothelioma, Malignant
2
Liver Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma
2
Anal Canal Carcinoma
2
Adenocarcinoma
2
von Hippel-Lindau Disease
1
Interventions
Ipilimumab
3
tremelimumab
1
tilsotolimod
1
spartalizumab
1
pembrolizumab
1
durvalumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Nivolumab
×
Clear all
NCT07000149
2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3
Active not recruiting
1,116 enrolled